Trials / Completed
CompletedNCT03922321
Study of RVT-1401 for the Treatment of Patients With Moderate to Severe Active Graves' Ophthalmopathy (GO)
A Phase 2a, Multicenter, Open-Label Study of RVT-1401 for the Treatment of Patients With Moderate to Severe Active Graves' Ophthalmopathy
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 7 (actual)
- Sponsor
- Immunovant Sciences GmbH · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study was to evaluate safety, tolerability, and pharmacodynamic parameters of RVT-1401 in graves' ophthalmopathy (GO) patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RVT-1401 | RVT-1401 is a fully human anti-neonatal Fc receptor (FcRn) monoclonal antibody. |
Timeline
- Start date
- 2019-04-22
- Primary completion
- 2020-02-29
- Completion
- 2020-05-21
- First posted
- 2019-04-19
- Last updated
- 2022-01-24
- Results posted
- 2022-01-24
Locations
4 sites across 1 country: Canada
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03922321. Inclusion in this directory is not an endorsement.